According to a summary provided by the Ministry of Health, 31 new molecules will be added to the list of reimbursable drugs as of January 1, 2025, 13 of which are used in oncology. Within this group, 7 therapies are drugs for patients with blood cancers, including B-cell lymphomas and acute myeloid leukemia.
- Since the inception of the HematoCoalition, in my speeches I often emphasize that in hematooncology modern drugs are of particular importance, as the number of available therapeutic options is limited in these indications. Therefore, any new therapy in these indications is very important. I am also extremely pleased to see the availability of subcutaneous immunotherapy with atezolizumab in lung cancer and changes in the B.56 program, the treatment of prostate cancer. These are cancers that are a... To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].Content locked
